Vignesh T Packiam

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1627805/publications.pdf

Version: 2024-02-01

71 papers

1,182 citations

394421 19 h-index 434195 31 g-index

72 all docs

72 docs citations

times ranked

72

1892 citing authors

#	Article	IF	Citations
1	An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim results. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 440-447.	1.6	140
2	Minimally Invasive Liver Resection: Robotic Versus Laparoscopic Left Lateral Sectionectomy. Journal of Gastrointestinal Surgery, 2012, 16, 2233-2238.	1.7	127
3	Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. European Urology, 2020, 78, 719-730.	1.9	73
4	Radiofrequency ablation compared to resection in earlyâ€stage hepatocellular carcinoma. Hpb, 2013, 15, 210-217.	0.3	48
5	Utilization and Outcomes of Nephroureterectomy for Upper Tract Urothelial Carcinoma by Surgical Approach. Journal of Endourology, 2017, 31, 661-665.	2.1	45
6	Extended Duration Enoxaparin Decreases the Rate of Venous Thromboembolic Events after Radical Cystectomy Compared to Inpatient Only Subcutaneous Heparin. Journal of Urology, 2017, 197, 302-307.	0.4	44
7	Non–muscleâ€invasive bladder cancer: Intravesical treatments beyond Bacille <scp>C</scp> almetteâ€ <scp>G</scp> uérin. Cancer, 2017, 123, 390-400.	4.1	37
8	Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage. Current Urology Reports, 2019, 20, 84.	2.2	36
9	The Impact of Minimally Invasive Surgery on Major latrogenic Ureteral Injury and Subsequent Ureteral Repair During Hysterectomy: A National Analysis of Risk Factors and Outcomes. Urology, 2016, 98, 183-188.	1.0	31
10	Rhabdomyolysis After Major Urologic Surgery: Epidemiology, Risk Factors, and Outcomes. Urology, 2015, 85, 1328-1332.	1.0	28
11	Presentation and outcomes of hepatocellular carcinoma patients at a western centre. Hpb, 2011, 13, 712-722.	0.3	27
12	DAP12 Promotes IRAK-M Expression and IL-10 Production by Liver Myeloid Dendritic Cells and Restrains Their T Cell Allostimulatory Ability. Journal of Immunology, 2011, 186, 1970-1980.	0.8	27
13	The Relationship between Sleep Disorders and Lower Urinary Tract Symptoms: Results from the NHANES. Journal of Urology, 2018, 200, 161-166.	0.4	27
14	Biomarkers Implicated in Lower Urinary Tract Symptoms: Systematic Review and Pathway Analyses. Journal of Urology, 2019, 202, 880-889.	0.4	27
15	Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate. Urology, 2015, 86, 777-782.	1.0	26
16	Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL: Results from a Multicenter Study in China. Prostate, 2017, 77, 1221	-1 2 29.	26
17	Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis. Journal of the National Cancer Institute, 2020, 112, 847-854.	6.3	23
18	30-Day Morbidity and Reoperation Following Midurethral Sling: Analysis of 8772 Cases Using a National Prospective Database. Urology, 2016, 95, 72-79.	1.0	19

#	Article	IF	CITATIONS
19	No Effect of Music on Anxiety and Pain During Transrectal Prostate Biopsies: A Randomized Trial. Urology, 2018, 117, 31-35.	1.0	19
20	Trends in Simple Prostatectomy for Benign Prostatic Hyperplasia. Current Urology Reports, 2016, 17, 57.	2.2	18
21	Lessons from 151 ureteral reimplantations for postcystectomy ureteroenteric strictures: A single-center experience over a decade. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 112.e19-112.e25.	1.6	18
22	Percutaneous Image-guided Core Needle Biopsy for Upper Tract Urothelial Carcinoma. Urology, 2020, 135, 95-100.	1.0	18
23	CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG) Journal of Clinical Oncology, 2022, 40, 4597-4597.	1.6	17
24	latrogenic Bladder Injury: National Analysis of 30-Day Outcomes. Urology, 2016, 97, 250-256.	1.0	16
25	Incidence, Risk Factors, and Outcomes for Rectal Injury During Radical Prostatectomy: A Population-based Study. European Urology Oncology, 2018, 1, 501-506.	5.4	16
26	The Impact of Lymphovascular Invasion on Risk of Upstaging and Lymph Node Metastasis at the Time of Radical Cystectomy. European Urology Focus, 2020, 6, 292-297.	3.1	15
27	The Effect of Obesity on Perioperative Outcomes for Open and Minimally Invasive Prostatectomy. Urology, 2017, 100, 111-116.	1.0	14
28	Cost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-Guérin-Unresponsive Carcinoma In Situ of the Bladder. Journal of Urology, 2021, 205, 1326-1335.	0.4	14
29	Partial versus radical nephrectomy in clinical T2 renal masses. International Journal of Urology, 2021, 28, 1149-1154.	1.0	14
30	Cost-Effectiveness of Maintenance bacillus Calmette-Guérin for Intermediate and High Risk Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2020, 204, 442-449.	0.4	13
31	Upstaging of nonurothelial histology in bladder cancer at the time of surgical treatment in the National Cancer Data Base. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 34.e1-34.e8.	1.6	12
32	The current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer. Current Opinion in Urology, 2021, 31, 178-187.	1.8	11
33	Open Vs Minimally Invasive Adult Ureteral Reimplantation: Analysis of 30-day Outcomes in the National Surgical Quality Improvement Program (NSQIP) Database. Urology, 2016, 94, 123-128.	1.0	10
34	Bladder Reconstruction with Bowel: Robot-Assisted Laparoscopic Ileocystoplasty with Mitrofanoff Appendicovesicostomy in Pediatric Patients. Journal of Endourology, 2018, 32, S-119-S-126.	2.1	10
35	Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial. Prostate, 2017, 77, 1179-1186.	2.3	9
36	Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 9.e1-9.e7.	1.6	9

#	Article	IF	Citations
37	The Impact of Perioperative Aspirin on Bleeding Complications Following Robotic Partial Nephrectomy. Journal of Endourology, 2016, 30, 997-1003.	2.1	8
38	Influence of pathologist experience on positive surgical margins following radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 461.e1-461.e6.	1.6	8
39	Redefining the implications of nasogastric tube placement following radical cystectomy in the alvimopan era. World Journal of Urology, 2017, 35, 625-631.	2.2	8
40	The role of inguinal lymph node dissection in men with urethral squamous cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 526.e1-526.e6.	1.6	8
41	The association of anxiety and depression with perioperative and oncologic outcomes among patients with clear cell renal cell carcinoma undergoing nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 41.e19-41.e27.	1.6	8
42	Attitudes and knowledge of urethral catheters: a targeted educational intervention. BJU International, 2016, 118, 654-659.	2.5	7
43	Simultaneous versus staged partial nephrectomies for bilateral synchronous solid renal masses. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 640.e13-640.e22.	1.6	7
44	The evolving role of lymphadenectomy for bladder cancer: why, when, and how. Translational Andrology and Urology, 2020, 9, 3082-3093.	1.4	7
45	Long-term outcomes of incidental prostate cancer at radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 848.e17-848.e22.	1.6	6
46	The emerging role of somatic tumor sequencing in the treatment of urothelial cancer. Asian Journal of Urology, 2021, 8, 391-399.	1,2	6
47	The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-institution analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 436.e1-436.e8.	1.6	6
48	The role of mycobacterial cell wall nucleic acid complex in the treatment of bacillus Calmette–Guérin failures for non-muscle-invasive bladder cancer. Therapeutic Advances in Urology, 2016, 8, 29-37.	2.0	5
49	Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non–Muscle-Invasive Bladder Cancer. Journal of Urology, 2022, 208, 969-977.	0.4	5
50	Tumor Enucleation is Appropriate During Partial Nephrectomy: Against. European Urology Focus, 2019, 5, 925-926.	3.1	4
51	Reply by the Authors. Urology, 2016, 97, 281.	1.0	3
52	National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 687.e13-687.e18.	1.6	3
53	Phase Ib study of avelumab and taxane based chemotherapy in platinum-refractory or ineligible metastatic urothelial cancer (AVETAX study) Journal of Clinical Oncology, 2022, 40, 503-503.	1.6	3
54	Prevalence, Predictors, and Oncologic Outcomes of Pelvic Organ Involvement in Women Undergoing Radical Cystectomy. Archives of Pathology and Laboratory Medicine, 2023, 147, 202-207.	2.5	3

#	Article	IF	Citations
55	Hospital-Based Analysis of Trends and Outcomes for Patients Undergoing Pyelolithotomy. Journal of Endourology, 2017, 31, 78-84.	2.1	2
56	Robot-Assisted Laparoscopic Adrenalectomy. Journal of Endourology, 2018, 32, S-82-S-87.	2.1	2
57	Association between perioperative morbidity and mortality after radical cystectomy: an opportunity to understand the complication snowball effect. Translational Andrology and Urology, 2019, 8, S261-S262.	1.4	2
58	Creation of a primary tumor tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 135.e1-135.e8.	1.6	2
59	Author Reply. Urology, 2016, 95, 78-79.	1.0	1
60	Ongoing efforts to reduce perioperative morbidity of radical cystectomy: towards widespread adoption of extended-duration thromboprophylaxis. Translational Andrology and Urology, 2018, 7, S81-S82.	1.4	1
61	Are We Moving Closer to Accurate Restaging after Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer?. European Urology, 2021, 79, 372-373.	1.9	1
62	Consensus statements from the EAU-ESMO collaboration for advanced and variant bladder cancer: can we move the needle to improve survival?. Translational Andrology and Urology, 2020, 9, 2488-2492.	1.4	1
63	Combined robotic radical prostatectomy and laparoscopic proctectomy for synchronous prostate and rectal cancer. Urology Case Reports, 2022, 42, 102043.	0.3	1
64	Minimal difference in survival between radical prostatectomy and observation in men with modest life expectancy. Evidence-Based Medicine, 2017, 22, 222-222.	0.6	0
65	Robotic Radical Prostatectomy: Margins Positivity and Implications on Cancer Control. , 2018, , 471-486.		0
66	The limits of complex partial nephrectomy: are there any?. Annals of Translational Medicine, 2019, 7, S345-S345.	1.7	0
67	Microscopic Hematuria: Diagnosis Is Only Half the Battle. European Urology, 2020, 77, 599-600.	1.9	0
68	The Association of Trainee Involvement in Radical Cystectomy With Perioperative and Oncologic Outcomes. Urology, 2022, , .	1.0	0
69	Sequential intravesical gemcitabine and docetaxel for BCG-naÃ ⁻ ve high-risk nonmuscle-invasive bladder cancer Journal of Clinical Oncology, 2022, 40, 497-497.	1.6	0
70	Sequential intravesical valrubicin and docetaxel for the treatment of nonmuscle invasive bladder cancer Journal of Clinical Oncology, 2022, 40, 496-496.	1.6	0
71	Long-term follow-up of intravesical gemcitabine and docetaxel as rescue therapy for nonmuscle-invasive bladder cancer Journal of Clinical Oncology, 2022, 40, 573-573.	1.6	0